PepGen's Q4 Net Loss Narrows to $18.3M, Cash Runway Extends into 2H 2027
PEPG has more than doubled off its 52-week low of $0.88.
Summary
Pepgen reported a Q4 net loss of $18.3 million, a narrowing from $22.2 million in the prior year, primarily due to decreased operating expenses. The company also highlighted a robust cash position of $148.5 million, which is projected to fund operations into the second half of 2027. This financial update, while showing some improvement in loss reduction and a solid cash runway, is released shortly after the company announced a partial clinical hold by the FDA on its pivotal FREEDOM2 trial. The regulatory setback is a more immediate and significant concern for a biotech firm, likely overshadowing the Q4 financial results. Investors will now closely monitor developments regarding the FDA hold and the anticipated data readouts for the FREEDOM2 trial in Q1 and 2H 2026.
At the time of this announcement, PEPG was trading at $5.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $464.7M. The 52-week trading range was $0.88 to $7.80. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.